From Surf Wiki (app.surf) — the open knowledge base

Temoporfin

Chemical compound

| Drugs.com =

| elimination_half-life =

Temoporfin (INN) is a photosensitizer (based on chlorin) used in photodynamic therapy for the treatment of squamous cell carcinoma of the head and neck. It is marketed in the European Union under the brand name Foscan. The U.S. Food and Drug Administration (FDA) declined to approve Foscan in 2000. The EU approved its use in June 2001.

Good results were obtained in 21 of 35 patients treated in Germany.

It is photoactivated at 652 nm by red light.

Patients can remain photosensitive for several weeks after treatment.

References

(April 2008). "[Squamous cell carcinoma of the head and neck. Photodynamic therapy with Foscan]". Hno.
"Foscan approval saves Scotia's skin.". HighBeam.
(December 2009). "Photodynamic therapy with meta-tetrahydroxyphenylchlorin (Foscan) in the management of squamous cell carcinoma of the head and neck: experience with 35 patients". European Archives of Oto-Rhino-Laryngology.

Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

photosensitizing-agents tetrapyrroles

Want to explore this topic further?

Ask Mako anything about Temoporfin — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report